The Medical Oncology Centre of Rosebank

Recent papers from The Medical Oncology Centre of Rosebank

1. Cancer drugs: Highlighting the molecular mechanisms of cardiotoxicitySA Heart · 2017
2. Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized StudyAdvances in Therapy · 2026
3. Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statementSupportive Care in Cancer · 2026
4. An updated and expanded Type classification scheme for diamonds based on FTIR spectroscopic dataAmerican Mineralogist · 2026
5. Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.Journal of Clinical Oncology · 2026
6. Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).Journal of Clinical Oncology · 2026
7. A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer.Journal of Clinical Oncology · 2026
8. Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging TargetCurrent Issues in Molecular Biology · 2026
9. A Global Delphi Consensus on Acne and the Microbiome: Integrating International Expertise for Innovative Prevention and Therapeutic StrategiesPharmaceuticals · 2026
10. Systemic Protein Biomarkers, Composite Blood Inflammatory Indices and Cellular Ratios in Metastatic Colorectal Cancer: Potential Therapeutic TargetsDiseases · 2026
11. Abstract CT224: Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (Teluride-006)Cancer Research · 2026
12. WBC Growth Factors: ASCO Guideline UpdateJournal of Clinical Oncology · 2026
13. Abstract PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro for previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)Clinical Cancer Research · 2026
14. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.2026
15. Low Internet Penetration in Sub-Saharan Africa and the Role of LEO Satellites in Addressing the IssueTelecom · 2026
16. Immunopathogenesis and Therapeutic Implications in Basal Cell Carcinoma: Current Concepts and Future DirectionsMedicina · 2025
17. Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell CarcinomaCancers · 2025
18. The health status of South African youth joining Youth Employment Initiatives: a health promotion opportunityHealth Promotion International · 2025
19. Diabetic Nephropathy-Associated Impaired Aortic Function Is Not Mediated by Mean Arterial Pressure and Its DeterminantsJournal of Clinical Medicine · 2024
20. Sodium, Potassium-Adenosine Triphosphatase as a Potential Target of the Anti-Tuberculosis Agents, Clofazimine and BedaquilineInternational Journal of Molecular Sciences · 2024